Current data reveals that stereotactic breast biopsy needles designated under FDA product code KNW are experiencing documented supply disruptions across U.S. healthcare facilities. This single device classification represents a critical diagnostic bottleneck affecting cancer screening and diagnostic capabilities nationwide.
The shortage of KNW-coded instruments has prompted formal FDA notification to healthcare providers, underscoring the severity and scope of the supply challenge. Healthcare systems are being urged to assess inventory status immediately and implement diagnostic care contingency plans to address potential procurement delays. Understanding the specific device classification affected helps clinicians identify alternative suppliers and plan resource allocation strategies during this shortage period.
Read the full article on GMJ Newsroom.
Was this article helpful?
